Rmf Dictagene S.a.

Institut Pasteur

Eniricerche S.p.a.

Univiersite De Lausanne

Université De Lausanne

Giampietro Corradin

Elisabetta Bianchi

Antonello Pessi

Pierre Druilhe

Christophe Dominique Reymond

Nicolas Joseph Fasel

Hans Peter Merkle

Christian P Roussilhon

Bruno Gander

Ali Jafarshad

Mario Rogerro

Claudio Thomasin

Ying Men

Mario Roggero

Christian Roussillhon

The present application relates to a sub-region of aprotein, with improved vaccine potential, and to medical uses thereof, notably for treatment or diagnosis of malaria. The present invention notably provides unstructured or unfolded polypeptides deriving from the PFF0165c protein of3D7. The polypeptides of the invention have a high antigenicity, a high immunogenicity, have a high parasite-killing activity in the ADCI assay, and are strongly associated with clinical protection against malaria, and. The present invention thereby provides a vaccine for the palliative and/or curative treatment of malaria, which is specifically intended for infants, toddlers, children under the age of 5, pregnant women.

Sub-region of a plasmodium protein with improved vaccine potential, and medical uses thereof

An immunological response potentiation process is disclosed for synthetic or genetically engineered antigens having low immunogenicity. The antigen is embedded into biodegradable microparticles, and the antigen-loaded microparticles are dispersed in a biodegradable medium. When parenterally administered, the antigen-loaded microparticles trigger a potentiated antibody, T -lymphocyte and T -lymphocyte response, as compared to an aqueous antigen solution. The extent of immunological potentiation is at least comparable with that attained by Incomplete Freund's adjuvant compositions. Linear B-T -cell epitopes, linear T -cell epitopes, dimers and multimers of those epitopes, and mixtures thereof, are used as low immunogenicity antigens. The microparticles are based on biodegradable biopolymers such as polyester, polyanhydride, and polyorthoester. By mixing microparticles with different wettabilities, swellabilities, release and biodegradation times, the most intense and longest immunological potentiation is achieved. This process is useful for immunizing humans and animals against diseases caused by viruses, bacteria, protozoa or tumor cells.

Immunological response potentiation process

The present invention relates to a vaccine against malaria comprising a polypeptide having the amino acid sequence of the C-terminal part of the circumsporozoite protein of a Plasmodium species, in which polypeptide one or more pairs of cysteine residues are oxidized, and optionally a suitable carrier and/or adjuvant and/or biodegradable microcapsules for use in humans.

Malaria vaccine

Preparation of purified (poly)peptides

The synthetic peptide TT3, the amino acid sequence of which corresponds to the region 947-967 of the tetanus toxin is recognized by different human Th cell clones in association with a wide range of alleles of the human major histocompatibility complex (MHC). Said peptide contains at least two epitopes, of which one (953-967) is recognized by the DR5-restricted clones and the other (947-960) is recognized by all other DR and DP alleles restricted clones. The TT3 peptide and the peptide corresponding to the 947-960 epitope can be used as universal carriers in the preparation of immunogenic conjugates consisting of at least one of said peptides and a natural or synthetic hapten derived from a pathogenic agent of interest. The immunogenic conjugates are particularly suitable for preparing synthetic vaccines able to provide a protective immunity against different pathogenic agents which is not genetically restricted or is only slightly genetically restricted.

Synthetic peptides useful as universal carriers for the preparation of

Growing community of inventors

Lausanne, Switzerland

Giampietro Corradin